IN2014MN02437A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02437A IN2014MN02437A IN2437MUN2014A IN2014MN02437A IN 2014MN02437 A IN2014MN02437 A IN 2014MN02437A IN 2437MUN2014 A IN2437MUN2014 A IN 2437MUN2014A IN 2014MN02437 A IN2014MN02437 A IN 2014MN02437A
- Authority
- IN
- India
- Prior art keywords
- lysin
- antibiotic
- bacteria
- linezolid
- oxacillin
- Prior art date
Links
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 108010013198 Daptomycin Proteins 0.000 abstract 1
- 241000192125 Firmicutes Species 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 abstract 1
- 229960005484 daptomycin Drugs 0.000 abstract 1
- 229960003907 linezolid Drugs 0.000 abstract 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 abstract 1
- 229960001019 oxacillin Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides compositions and methods for prevention amelioration and treatment of gram positive bacteria particularly bacteria with combinations of lysin particularly Streptococcal lysin particularly the lysin PlySs2 and one or more antibiotic including daptomycin vancomycin oxacillin linezolid or related antibiotic(s).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644944P | 2012-05-09 | 2012-05-09 | |
| US201261737239P | 2012-12-14 | 2012-12-14 | |
| PCT/US2013/040329 WO2013170015A1 (en) | 2012-05-09 | 2013-05-09 | Bacteriophage lysin and antibiotic combinations against gram positive bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02437A true IN2014MN02437A (en) | 2015-07-10 |
Family
ID=49551273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2437MUN2014 IN2014MN02437A (en) | 2012-05-09 | 2013-05-09 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10813983B2 (en) |
| EP (2) | EP2849782B1 (en) |
| JP (4) | JP6608697B2 (en) |
| KR (3) | KR20210121313A (en) |
| CN (1) | CN104736172A (en) |
| AU (3) | AU2013259512B2 (en) |
| BR (1) | BR112014027842A2 (en) |
| CA (1) | CA2872902A1 (en) |
| DK (1) | DK2849782T3 (en) |
| ES (1) | ES2784136T3 (en) |
| HK (2) | HK1208799A1 (en) |
| IL (3) | IL235527B2 (en) |
| IN (1) | IN2014MN02437A (en) |
| MX (2) | MX2014013586A (en) |
| RU (2) | RU2018121290A (en) |
| WO (1) | WO2013170015A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2849782B1 (en) | 2012-05-09 | 2020-03-18 | Contrafect Corporation | Bacteriophage lysin and antibiotic combinations against gram positive bacteria |
| CA2872911C (en) | 2012-05-09 | 2023-10-03 | Contrafect Corporation | Biofilm prevention, disruption and treatment with bacteriophage lysin |
| AU2015279705B2 (en) * | 2014-06-26 | 2021-04-01 | The Rockefeller University | Acinetobacter lysins |
| SG11201707345VA (en) * | 2015-03-12 | 2017-10-30 | Micreos Human Health Bv | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection |
| BR112018005318A2 (en) * | 2015-09-17 | 2018-12-11 | Contrafect Corporation | ? lysine polypeptides active against gram-negative bacteria? |
| US10851401B2 (en) * | 2016-05-12 | 2020-12-01 | Contrafect Corporation | Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides |
| DK3641753T3 (en) * | 2017-06-19 | 2022-12-12 | Univ Syddansk | BACITRACIN AND/OR DAPTOMYCIN COMBINED WITH CANNABIDIOL FOR THE TREATMENT OF BACTERIAL INFECTIONS |
| US20220023399A1 (en) * | 2017-07-10 | 2022-01-27 | Contrafect Corporation | Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof |
| MX2020008860A (en) * | 2018-02-26 | 2020-12-10 | Contrafect Corp | Modified plyss2 lysins and uses thereof. |
| CA3104650A1 (en) * | 2018-06-22 | 2019-12-26 | Contrafect Corporation | Lysins and derivatives thereof resensitize staphylococcus aureus and gram-positive bacteria to antibiotics |
| CN109668873B (en) * | 2018-12-05 | 2021-03-16 | 山东恒业生物技术有限公司 | Live vector vaccine activity detection device and use method thereof |
| US20220125860A1 (en) * | 2019-02-05 | 2022-04-28 | Elanco Us Inc. | Probiotic compositions comprising lactobacillus reuteri strains and methods of use |
| JP2022525914A (en) * | 2019-03-22 | 2022-05-20 | コントラフェクト コーポレイション | How to treat infective endocarditis |
| WO2020210691A1 (en) * | 2019-04-11 | 2020-10-15 | Contrafect Corporation | Method of treating and preventing bone and joint infections |
| EP4076420A4 (en) * | 2019-12-19 | 2024-03-13 | Georgia State University Research Foundation, Inc. | Compounds for the treatment of bacterial infections and potentiation of antibiotics |
| IL297953A (en) * | 2020-05-19 | 2023-01-01 | Contrafect Corp | Modified plyss2 lysins and antibiotic combinations for use against gram-positive bacteria |
| RU2755817C1 (en) * | 2020-07-22 | 2021-09-21 | Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" | Method for reducing gram-positive avian gut microbiota |
| KR102528412B1 (en) * | 2020-09-08 | 2023-05-04 | 클립스비엔씨 주식회사 | A Novel Composition for Preventing or Treating Staphylococcus aureus infectious diseases |
| WO2022261360A1 (en) * | 2021-06-09 | 2022-12-15 | Contrafect Corporation | Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria |
| CN115105491B (en) * | 2022-07-08 | 2023-12-22 | 东北农业大学 | Application of serine in preparation of medicines for inhibiting streptococcus suis |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1301645C (en) | 1986-10-08 | 1992-05-26 | David Bernstein | Method for exposing group a streptococcal antigens and an improved diagnostictest for the identification of group a streptococci |
| ZA883887B (en) | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| WO1997039111A1 (en) * | 1996-04-15 | 1997-10-23 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
| WO2000050069A1 (en) | 1999-02-25 | 2000-08-31 | New Horizons Diagnostics, Inc. | A means for the prophylactic and therapeutic treatment of streptococcal infections |
| US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
| US6248324B1 (en) | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
| US20060292135A1 (en) | 1997-10-31 | 2006-12-28 | Lawrence Loomis | Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| US6254866B1 (en) | 1997-10-31 | 2001-07-03 | New Horizons Diagnostics Corporation | Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract |
| US6264945B1 (en) | 1997-10-31 | 2001-07-24 | Vincent A Fischetti | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| US6056955A (en) | 1999-09-14 | 2000-05-02 | Fischetti; Vincent | Topical treatment of streptococcal infections |
| US6444813B2 (en) | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
| CA2486280A1 (en) | 2002-05-17 | 2004-04-01 | New Horizons Diagnostics Corporation | Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| US7569223B2 (en) | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
| EP1744779A2 (en) | 2004-03-24 | 2007-01-24 | The Rockfeller University | Lytic enzymes and spore surface antigen for detection and treatment of "bacillus anthracis" bacteria and spores |
| US8389469B2 (en) | 2005-06-06 | 2013-03-05 | The Rockefeller University | Bacteriophage lysins for Bacillus anthracis |
| US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
| WO2007024628A2 (en) | 2005-08-24 | 2007-03-01 | The Rockefeller University | Ply-gbs mutant lysins |
| WO2009029192A1 (en) | 2007-08-24 | 2009-03-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Surfactant-based antimicrobial solution for inhalation |
| CA2729160C (en) * | 2008-07-03 | 2017-11-14 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
| KR101016918B1 (en) | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | Novel Lysin Protein Having Broad Antibacterial Activity Specific to Bacteria |
| CN103080307A (en) | 2010-01-25 | 2013-05-01 | 美艾利尔斯卡保罗有限公司 | A25 bacteriophage lysin |
| US20120271770A1 (en) * | 2011-04-20 | 2012-10-25 | Visa International Service Association | Managing electronic tokens in a transaction processing system |
| CN107189997A (en) | 2011-04-21 | 2017-09-22 | 洛克菲勒大学 | The streptococcus bacteriophage lysin for detecting and treating for gram-positive bacteria |
| WO2012145573A2 (en) * | 2011-04-21 | 2012-10-26 | Universiteit Utrecht Holding Bv | Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock |
| US9016640B2 (en) | 2011-04-22 | 2015-04-28 | Rks Design, Inc. | Instrument retention assembly |
| WO2012146738A1 (en) | 2011-04-27 | 2012-11-01 | Lysando Holding Ag | New antimicrobial agents |
| EP2849782B1 (en) | 2012-05-09 | 2020-03-18 | Contrafect Corporation | Bacteriophage lysin and antibiotic combinations against gram positive bacteria |
| CA2872911C (en) * | 2012-05-09 | 2023-10-03 | Contrafect Corporation | Biofilm prevention, disruption and treatment with bacteriophage lysin |
-
2013
- 2013-05-09 EP EP13787128.1A patent/EP2849782B1/en active Active
- 2013-05-09 EP EP20158873.8A patent/EP3685851A1/en active Pending
- 2013-05-09 KR KR1020217031525A patent/KR20210121313A/en not_active Application Discontinuation
- 2013-05-09 CA CA2872902A patent/CA2872902A1/en active Pending
- 2013-05-09 RU RU2018121290A patent/RU2018121290A/en unknown
- 2013-05-09 JP JP2015511698A patent/JP6608697B2/en active Active
- 2013-05-09 KR KR1020237023634A patent/KR20230113404A/en active Application Filing
- 2013-05-09 IL IL235527A patent/IL235527B2/en unknown
- 2013-05-09 CN CN201380036510.8A patent/CN104736172A/en active Pending
- 2013-05-09 BR BR112014027842A patent/BR112014027842A2/en not_active Application Discontinuation
- 2013-05-09 IN IN2437MUN2014 patent/IN2014MN02437A/en unknown
- 2013-05-09 WO PCT/US2013/040329 patent/WO2013170015A1/en active Application Filing
- 2013-05-09 ES ES13787128T patent/ES2784136T3/en active Active
- 2013-05-09 MX MX2014013586A patent/MX2014013586A/en unknown
- 2013-05-09 IL IL308477A patent/IL308477A/en unknown
- 2013-05-09 KR KR1020147034614A patent/KR102310387B1/en active Application Filing
- 2013-05-09 DK DK13787128.1T patent/DK2849782T3/en active
- 2013-05-09 US US14/399,575 patent/US10813983B2/en active Active
- 2013-05-09 AU AU2013259512A patent/AU2013259512B2/en active Active
- 2013-05-09 RU RU2014149351A patent/RU2659208C2/en active
- 2013-06-04 US US13/909,618 patent/US9889181B2/en active Active
-
2014
- 2014-11-07 MX MX2021011843A patent/MX2021011843A/en unknown
-
2015
- 2015-09-24 HK HK15109410.6A patent/HK1208799A1/en unknown
- 2015-12-16 HK HK15112347.8A patent/HK1211484A1/en unknown
-
2017
- 2017-12-20 US US15/848,886 patent/US20180221456A1/en not_active Abandoned
-
2018
- 2018-04-24 AU AU2018202845A patent/AU2018202845B2/en active Active
- 2018-04-27 JP JP2018086685A patent/JP2018138045A/en not_active Withdrawn
-
2019
- 2019-12-06 JP JP2019221319A patent/JP2020054370A/en active Pending
-
2020
- 2020-05-21 IL IL274832A patent/IL274832A/en unknown
- 2020-09-16 AU AU2020233683A patent/AU2020233683A1/en not_active Abandoned
- 2020-09-25 US US17/033,195 patent/US20210008175A1/en not_active Abandoned
-
2021
- 2021-01-05 US US17/141,692 patent/US20210128696A1/en not_active Abandoned
-
2022
- 2022-01-20 JP JP2022007043A patent/JP2022058682A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02437A (en) | ||
| MX2023003461A (en) | Treatment of clostridium difficile infection. | |
| MX2017014020A (en) | Antimicrobial therapy. | |
| PH12015502401A1 (en) | Compositions and methods for enhancing microbial stability | |
| TR201820333T4 (en) | Compositions Containing Bacterial Strains | |
| PH12016501512B1 (en) | Treatment for resistant acne | |
| MX2019009132A (en) | Synergistic bacterial compositions and methods of production and use thereof. | |
| ZA201908447B (en) | Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections | |
| IN2014MN02438A (en) | ||
| MX2013006873A (en) | A composition comprising an antibiotic and a dispersant or an anti -adhesive agent. | |
| GB2530921A (en) | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficency | |
| GB2548277A (en) | Antibiofilm compositions | |
| GB2543453A (en) | Acinetobacter lysins | |
| HRP20170987T1 (en) | Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states | |
| PH12014501239A1 (en) | Thymol and totarol antibacterial composition | |
| AU2016323967A8 (en) | Compositions and methods for the treatment and prevention of radiation dermatitis | |
| SG11201702011SA (en) | Agent for promoting growth of nonpathogenic oral indigenous bacteria or agent for improving oral bacterial flora, and composition for oral use | |
| MX2018007838A (en) | Mucin coated silica for bacterial aggregation. | |
| WO2018083314A3 (en) | Use of phenothiazine derivative in the treatment of infectious purpura or purpura fulminans | |
| IN2014CN03886A (en) | ||
| WO2015063608A3 (en) | Prevention and dispersion of biolfilm | |
| MX2013012603A (en) | Liposomal vancomycin for the treatment of mrsa infections. | |
| MY167425A (en) | An antimicrobial composition for inhibiting bacterial biofilm | |
| MX2015009505A (en) | In vitro antimicrobial activity from the combination of scorpion anti-biocidal peptides with common use antibiotics. | |
| UA90789U (en) | Method for preventing suppurative complications and wound infection following tooth extraction using bacterial suspension of bacillus subtilis 090 |